GE HealthCare Technologies Inc. filings document formal disclosures for a medical technology and diagnostics company, including Form 8-K reports on results of operations and financial condition, material agreements, capital-structure matters, and governance changes. Recent current reports include earnings releases, a senior unsecured revolving credit facility, and board-related disclosures.
The company’s proxy materials describe annual-meeting matters, director elections, board committee assignments, executive compensation, equity awards, and shareholder voting procedures. GEHC filings also provide formal context for segment performance, liquidity arrangements, credit covenants, and governance matters tied to its healthcare technology, software, and pharmaceutical diagnostics businesses.
GE HealthCare Technologies director Rodney F. Hochman reported a small open-market purchase of company stock. A family trust bought 1,618 shares of common stock at $62.03 per share. Following the transactions, he holds 19,886 shares directly and 1,618 shares indirectly through the family trust.
GE HealthCare Technologies Inc. director Phoebe L. Yang Watkin reported acquiring additional common stock. On May 8, 2026, she made an open-market purchase of 1,000 shares at a weighted average price of $63.0063 per share. After this trade, she directly held 13,702 shares.
On May 7, 2026, she also received an award of 3,586 restricted stock units. Each unit represents the right to receive one share of GE HealthCare common stock, with 100% of the units vesting on the earlier of the company’s next annual stockholders meeting or May 7, 2027, subject to the plan terms and any deferral elections.
CULP H LAWRENCE JR reported acquisition or exercise transactions in this Form 4 filing.
GE HealthCare Technologies Inc. director H. Lawrence Culp Jr. reported equity-based compensation awards rather than open-market trades. He received 4,157 restricted stock units and 3,586 fully vested deferred stock units of common stock, both at no cash cost, as part of director compensation. Following these awards, he holds additional common stock directly and also indirectly through family trusts and a holding company.
GE HealthCare Technologies Inc. director Rodney F. Hochman reported equity awards under the company’s non-employee director plan. On May 7, 2026, he acquired 2,689 restricted stock units that will vest 100% on the earlier of the next annual stockholders’ meeting or May 7, 2027.
He also received 3,586 fully vested deferred stock units in lieu of 100% of his cash retainer, consistent with his election under GE HealthCare’s Non-Employee Director Compensation and Benefits Plan. Each restricted or deferred stock unit represents the right to receive one share of GE HealthCare common stock at settlement.
LESJAK CATHERINE A reported acquisition or exercise transactions in this Form 4 filing.
GE HealthCare Technologies Inc. director Catherine A. Lesjak received an award of 3,586 restricted stock units of GE HealthCare common stock on May 7, 2026. Each unit represents the right to receive one share of common stock at settlement and was granted at no cash cost to her.
The award will vest 100% on the earlier of GE HealthCare’s next annual meeting of stockholders or May 7, 2027. As a result of this compensation-related equity grant, Lesjak’s direct ownership reported in this filing increased to 12,702 shares of common stock, with settlement of vested units potentially deferred under the company’s Non-Employee Director Compensation and Benefits Plan.
Lobo Kevin reported acquisition or exercise transactions in this Form 4 filing.
GE HealthCare Technologies Inc. director Kevin Lobo reported an equity award of restricted stock units covering 3,586 shares of common stock. The award represents a grant, not an open-market purchase, and increased his direct holdings to 4,363 shares.
The filing notes that 100% of these restricted stock units will vest on the earlier of the company’s next annual meeting of stockholders or May 7, 2027. Each unit delivers one share of GE HealthCare common stock at settlement, and settlement may be deferred under the company’s Non-Employee Director Compensation and Benefits Plan.
Madden Anne T reported acquisition or exercise transactions in this Form 4 filing.
GE HealthCare Technologies Inc. director Anne T. Madden reported equity compensation awards in the form of company stock. She received 2,282 restricted stock units that will vest 100% on the earlier of the next GE HealthCare annual stockholder meeting or May 7, 2027. She also received 3,586 fully vested deferred stock units after electing to take her cash retainer as stock units under the Non-Employee Director Compensation and Benefits Plan. Each unit represents the right to receive one share of GE HealthCare common stock at settlement, and settlement of vested units may be deferred according to her plan elections. Following these awards, one transaction line shows she directly holds 19,479 shares of common stock.
GE HealthCare Technologies Inc. director William J. Stromberg reported a compensation-related equity grant. On May 7, 2026, he acquired 3,586 restricted stock units (RSUs), each representing one future share of common stock. These RSUs vest 100% on the earlier of the company’s next annual stockholder meeting or May 7, 2027. Stromberg can elect to defer settlement under GE HealthCare’s Non-Employee Director Compensation and Benefits Plan, meaning the actual delivery of shares can occur later according to his deferral election. Following this award, his direct holdings reported in this filing total 18,916 shares of common stock.
GE HealthCare Technologies Inc. held its annual stockholder meeting on May 7, 2026, where eight directors were elected to one-year terms. Vote totals for each nominee were strong, with Peter J. Arduini receiving 363,637,737 votes for and H. Lawrence Culp, Jr. receiving 351,620,004 votes for.
Stockholders approved the advisory vote on named executive officer compensation with 351,099,781 votes for and 12,973,200 against. They also ratified Deloitte & Touche LLP as independent auditor for the fiscal year ending December 31, 2026, with 398,257,878 votes for and 769,608 against.
Effective May 7, 2026, the Board appointed Rodney F. Hochman as independent lead director and named Anne T. Madden as chairperson of the Nominating and Governance Committee, signaling updated leadership roles within the board structure.
GE HealthCare Technologies director H. Lawrence Culp Jr. reported an open-market purchase of 80,805 shares of common stock at a weighted average price of $61.8783 per share, with individual trades between $61.50 and $62.22. Following this transaction, he indirectly holds 151,207 shares through a holding company, 328,268 shares through family trusts, and 12,699 shares directly.